Allergan plc is an American, Irish-domiciled pharmaceutical company that offers brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

According to the law firm press release, the lawsuit alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Allergan and Actavis were engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice ("DOJ"); (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Allergan and Actavis by the end of 2016 for suspected price collusion; (3) in turn, Allergan and Actavis lacked effective internal controls; and (4) as a result, Allergan’s and Actavis’s public statements were materially false and misleading at all relevant times.

The first filed action was voluntarily dismissed on January 2, 2017. However, this action continues under a related filing, in the District of New Jersey, Forden v. Allergan PLC, et al., No. 16-cv-9499. On May 1, Plaintiffs filed a consolidated amended Complaint. On November 28, Plaintiffs filed a consolidated second amended Complaint. On January 22, 2018, Defendants filed a Motion to Dismiss the consolidated second amended Complaint. The Court issued an Order on August 6, 2019, denying Defendants' Motion to Dismiss.

The parties entered into a Stipulation and Agreement of Settlement on July 8, 2021. The Court granted preliminary approval of the Settlement on July 30. On November 22, the Court granted final approval of the Settlement and entered Final Judgment.

On December 27, 2023, the Court issued an Order approving disbursement of the Settlement Funds.